Literature DB >> 2550243

Acute calcium entry blockade inhibits the blood pressure but not the hormonal responses to angiotensin II.

J Staessen1, R Fagard, P Hespel, P Lijnen, E Moerman, A Amery.   

Abstract

The effects of acute calcium entry blockade by isradipine (IS) and placebo (P) on the haemodynamic and humoral responses to angiotensin II (A II) have been compared in two groups of 9 patients with essential hypertension. During 4 sequential periods each of 20 min, an i.v. infusion of A II 0, 2, 4 and 8 ng.kg-1.min-1 was given before (control) and 30 min after the oral administration either of IS or P. After IS, both the blood pressure and the angiotensin II-induced pressor effect were significantly reduced. Isradipine increased the heart rate and this cardio-acceleration was potentiated by A II. In contrast, when A II was infused in the absence of IS, heart rate tended to decrease. IS stimulated plasma renin activity and reduced plasma aldosterone. However, it did not affect either the inhibition of plasma renin activity or the rise in plasma aldosterone in response to A II. In conclusion, acute calcium entry blockade in patients with essential hypertension reduces the pressor response to A II, but not the A II-induced inhibition of renin and increase in plasma aldosterone.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550243     DOI: 10.1007/BF00637737

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  38 in total

1.  Acute haemodynamic and humoral responses to felodipine and metoprolol in mild hypertension.

Authors:  R Fagard; P Lijnen; E Moerman; J Staessen; A Amery
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Calcium dependence of the inhibitory effect of angiotensin on renin secretion in the isolated perfused kidney of the rat.

Authors:  R Van Dongen; W S Peart
Journal:  Br J Pharmacol       Date:  1974-01       Impact factor: 8.739

3.  Mechanism of action of angiotensin in smooth muscle cell. Biochemical changes following interaction of the hormone with its membrane receptors.

Authors:  G A d' Auriac; M Baudouin; P Meyer
Journal:  Circ Res       Date:  1972-09       Impact factor: 17.367

4.  Effects of intravenous and oral verapamil upon pressor and adrenal steroidogenic responses in normal man.

Authors:  G P Guthrie; R G McAllister; T A Kotchen
Journal:  J Clin Endocrinol Metab       Date:  1983-08       Impact factor: 5.958

5.  Quantitation of catecholamines in urine and in plasma.

Authors:  E J Moerman; A F De Schaepdryver
Journal:  Clin Chim Acta       Date:  1984-06-13       Impact factor: 3.786

6.  Direct radioimmunoassay of plasma aldosterone in normal subjects.

Authors:  P Lijnen; A Amery; R Fagard; P Corvol
Journal:  Clin Chim Acta       Date:  1978-03-15       Impact factor: 3.786

7.  Altered pressor responses in long-term nitrendipine treatment.

Authors:  G Simon; D K Snyder
Journal:  Clin Pharmacol Ther       Date:  1984-09       Impact factor: 6.875

8.  Effect of nifedipine on blood pressure and adrenocortical responses to trophic stimuli in humans.

Authors:  J A Millar; A D Struthers; G H Beastall; J L Reid
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

9.  Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man.

Authors:  N K Hollenberg; W R Chenitz; D F Adams; G H Williams
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

10.  PN 200-110, a new calcium antagonist: electrophysiological, inotropic, and chronotropic effects on guinea pig myocardial tissue and effects on contraction and calcium uptake of rabbit aorta.

Authors:  R P Hof; G Scholtysik; R Loutzenhiser; H J Vuorela; P Neumann
Journal:  J Cardiovasc Pharmacol       Date:  1984 May-Jun       Impact factor: 3.105

View more
  1 in total

Review 1.  Molecular and clinical investigations in patients with low-renin hypertension.

Authors:  Isla S Mackenzie; Morris J Brown
Journal:  Clin Exp Nephrol       Date:  2008-08-15       Impact factor: 2.801

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.